DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 27, 2018, reports the cash position of DBV Technologies S.A. as of March 31, 2018. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company is headquartered in Montrouge, France, with additional operations in New York, NY.
Key Financial Metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents (March 31, 2018) | €234.5 million |
| Cash and Cash Equivalents (December 31, 2017) | €137.9 million |
| Outstanding Ordinary Shares (March 31, 2018) | 29,718,352 |
| Fully Diluted Shares (March 31, 2018) | 32,272,620 |
The filing does not provide data on revenue, profit, operating cash flow, margins, or debt levels for the period.
Material Changes
Cash and cash equivalents increased by €96.6 million, representing a 70% increase from €137.9 million as of December 31, 2017, to €234.5 million as of March 31, 2018. The number of outstanding shares remained at 29,718,352, with fully diluted shares calculated at 32,272,620.
Outlook, Risks, and Management Commentary
Management highlighted ongoing clinical trials for Viaskin Peanut and Viaskin Milk, as well as preclinical development for Viaskin Egg. The company is also pursuing a human proof-of-concept study for Viaskin Milk to treat Eosinophilic Esophagitis and exploring applications in vaccines. The filing does not contain specific forward-looking financial guidance, risk factors, or discussion of contingencies beyond the general description of clinical development stages.
Key Facts for Investor Verification
- Verify the source of the €96.6 million increase in cash (e.g., equity financing, debt issuance, or operational cash flow) as the filing does not specify the cause.
- Confirm the status and timelines of the ongoing clinical trials for Viaskin Peanut and Viaskin Milk.
- Review the company's burn rate and runway given the lack of reported revenue in this filing.
- Check for any recent equity issuances that may have contributed to the cash increase, noting the difference between outstanding and fully diluted shares.